These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 11421528)

  • 1. Testosterone treatment in hypogonadal men: prostate-specific antigen level and risk of prostate cancer.
    Guay AT; Perez JB; Fitaihi WA; Vereb M
    Endocr Pract; 2000; 6(2):132-8. PubMed ID: 11421528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate-specific antigen changes in hypogonadal men treated with testosterone replacement.
    Gerstenbluth RE; Maniam PN; Corty EW; Seftel AD
    J Androl; 2002; 23(6):922-6. PubMed ID: 12399540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less.
    Morgentaler A; Rhoden EL
    Urology; 2006 Dec; 68(6):1263-7. PubMed ID: 17169647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy.
    Rhoden EL; Morgentaler A
    Int J Impot Res; 2006; 18(2):201-5. PubMed ID: 16177827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia.
    Rhoden EL; Morgentaler A
    J Urol; 2003 Dec; 170(6 Pt 1):2348-51. PubMed ID: 14634413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate size in hypogonadal men treated with a nonscrotal permeation-enhanced testosterone transdermal system.
    Meikle AW; Arver S; Dobs AS; Adolfsson J; Sanders SW; Middleton RG; Stephenson RA; Hoover DR; Rajaram L; Mazer NA
    Urology; 1997 Feb; 49(2):191-6. PubMed ID: 9037280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men.
    Arver S; Dobs AS; Meikle AW; Caramelli KE; Rajaram L; Sanders SW; Mazer NA
    Clin Endocrinol (Oxf); 1997 Dec; 47(6):727-37. PubMed ID: 9497881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of Prostate Biopsy in Men with Hypogonadism Prior or During Testosterone Replacement Therapy.
    Shoskes DA; Barazani Y; Fareed K; Sabanegh E
    Int Braz J Urol; 2015; 41(6):1167-71. PubMed ID: 26742976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-specific antigen (PSA) concentrations in hypogonadal men during 6 years of transdermal testosterone treatment.
    Raynaud JP; Gardette J; Rollet J; Legros JJ
    BJU Int; 2013 May; 111(6):880-90. PubMed ID: 23294726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of parenteral testosterone replacement on prostate specific antigen in hypogonadal men with erectile dysfunction.
    Svetec DA; Canby ED; Thompson IM; Sabanegh ES
    J Urol; 1997 Nov; 158(5):1775-7. PubMed ID: 9334599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of testosterone replacement therapy on prostate-specific antigen (PSA) levels in men being treated for hypogonadism: a systematic review and meta-analysis.
    Kang DY; Li HJ
    Medicine (Baltimore); 2015 Jan; 94(3):e410. PubMed ID: 25621688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
    Coward RM; Simhan J; Carson CC
    BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate-Specific Antigen Levels During Testosterone Treatment of Hypogonadal Older Men: Data from a Controlled Trial.
    Cunningham GR; Ellenberg SS; Bhasin S; Matsumoto AM; Parsons JK; Preston P; Cauley JA; Gill TM; Swerdloff RS; Wang C; Ensrud KE; Lewis CE; Pahor M; Crandall JP; Molitch ME; Cifelli D; Basaria S; Diem SJ; Stephens-Shields AJ; Hou X; Snyder PJ
    J Clin Endocrinol Metab; 2019 Dec; 104(12):6238-6246. PubMed ID: 31504596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clomiphene citrate: A potential alternative for testosterone therapy in hypogonadal males.
    Huijben M; Lock MTWT; de Kemp VF; Beck JJH; De Kort LMO; van Breda HMK
    Endocrinol Diabetes Metab; 2023 May; 6(3):e416. PubMed ID: 36998229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men.
    Debruyne FM; Behre HM; Roehrborn CG; Maggi M; Wu FC; Schröder FH; Jones TH; Porst H; Hackett G; Wheaton OA; Martin-Morales A; Meuleman E; Cunningham GR; Divan HA; Rosen RC;
    BJU Int; 2017 Feb; 119(2):216-224. PubMed ID: 27409523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of exogenous testosterone replacement on prostate-specific antigen and prostate-specific membrane antigen levels in hypogonadal men.
    Douglas TH; Connelly RR; McLeod DG; Erickson SJ; Barren R; Murphy GP
    J Surg Oncol; 1995 Aug; 59(4):246-50. PubMed ID: 7543173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation between simultaneous PSA and serum testosterone concentrations among eugonadal, untreated hypogonadal and hypogonadal men receiving testosterone replacement therapy.
    Grober ED; Lamb DJ; Khera M; Murthy L; Lipshultz LI
    Int J Impot Res; 2008; 20(6):561-5. PubMed ID: 18843272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostatic specific antigen in patients with hypogonadism: effect of testosterone replacement.
    El-Sakka AI; Hassoba HM; Elbakry AM; Hassan HA
    J Sex Med; 2005 Mar; 2(2):235-40. PubMed ID: 16422891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterising the safety of clomiphene citrate in male patients through prostate-specific antigen, haematocrit, and testosterone levels.
    Chandrapal JC; Nielson S; Patel DP; Zhang C; Presson AP; Brant WO; Myers JB; Hotaling JM
    BJU Int; 2016 Dec; 118(6):994-1000. PubMed ID: 27226135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of androgen deficiency and replacement on prostate zonal volumes.
    Jin B; Conway AJ; Handelsman DJ
    Clin Endocrinol (Oxf); 2001 Apr; 54(4):437-45. PubMed ID: 11318778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.